Deal Watch: Mylan Counts On A Renaissance For Expansion
Executive Summary
European markets are the name of the game as Ariad sells its European business to Incyte, Spain's Grupo Ferrer buys out Alexza, Italy's Chiesi bags a suite of CV drugs from The Medicines Co. and Swiss kidney disease specialist Vifor Fresenius takes up Opko's Rayaldee.
You may also be interested in...
Mylan Confident On Advair Generic First-Round Approval
President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.
Mylan Finally Nabs Meda In Diversification Play
Deal coincides with full year/fourth quarter earnings release.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.